[1] Zhou P, Yang XL, Wang XG, et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature,2020,579(7798):270-273.
[2] Huang C, Wang Y, Li X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet,2020,395(10223):497-506.
[3] Li Z, Yi Y, Luo X, et al.Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis[J]. J Med Virol,2020,92(9):1518-1524.
[4] Graham BS.Rapid COVID-19 vaccine development[J]. Science,2020,368(6494):945-946.
[5] Lavigne SE.The race for a COVID-19 vaccine[J]. Can J Dent Hyg,2020,54(3):107-109.
[6] Jacobs D.Antibiotics for appendicitis-proceed with caution[J]. N Engl J Med,2020,383(20):1985-1986.
[7] Pulendran B, Ahmed R.Immunological mechanisms of vaccination[J]. Nat Immunol,2011,12(6):509-517.
[8] Wang H, Zhang Y, Huang B, et al.Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2[J]. Cell,2020,182(3):713-721.
[9] Yu JY, Tostanoski LH, Peter L, et al.DNA vaccine protection against SARS-CoV-2 in rhesus macaques[J]. Science,2020,369(6065):806-811.
[10] Jackson LA, Anderson EJ, Rouphael NG, et al.An mRNA vaccine against SARS-CoV-2- preliminary report[J]. N Engl J Med,2020,383(20):1920-1931.
[11] Vartak A, Sucheck SJ.Recent advances in subunit vaccine carriers[J]. Vaccines (Basel),2016,4(2):12-30.
[12] Mueller S, Stauft CB, Kalkeri R, et al.A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates[J]. Vaccine,2020,38(14):2943-2948.
[13] Xia S, Duan K, Zhang Y, et al.Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials[J]. JAMA,2020,324(10):951-960.
[14] Zhang YJ, Zeng G, Pan H, et al.Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial[J]. Lancet Infect Dis,2020,2(21):181-192.
[15] Xia S, Zhang Y, Wang Y, et al.Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial[J]. Lancet Infect Dis,2021,21(1):39-51.
[16] Yang J, Wang W, Chen Z, et al.A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity[J]. Nature,2020,586(7830):572-577.
[17] Smith TRF, Patel A, Ramos S, et al.Immunogenicity of a DNA vaccine candidate for COVID-19[J]. Nat Commun,2020,11(1):2601-2614.
[18] Pagliusi S, Jarrett S, Hayman B, et al.Emerging manufacturers engagements in the COVID-19 vaccine research, development and supply[J]. Vaccine,2020,38(34):5418-5423.
[19] Polack FP, Thomas SJ, Kitchin N, et al.Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine[J]. N Engl J Med,2020,383(27):2603-2615.
[20] Mulligan MJ, Lyke KE, Kitchin N, et al.Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults[J]. Nature,2020,586(7830):589-593.
[21] Reuters. China starts work on plant for mRNA-based COVID-19 vaccine candidate-media[EB/OL].(2020-12-21)[2021-07-24]. https://www.newsbreak.com/news/2129956924593/china-starts-work-on-plant-for-mrna-based-covid-19-vaccine-candidate-media.
[22] Laczko D, Hogan MJ, Toulmin SA, et al.A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice[J]. Immunity,2020,53(4):724-732.
[23] Dai L, Zheng T, Xu K, et al.A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS[J]. Cell,2020,182(3):722-733 e711.
[24] Keech C, Albert G, Cho I, et al.Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine[J]. N Engl J Med,2020,383(24):2320-2332.
[25] Moscato J. Generex biotechnology provides guidance on the safety of Ii-Key peptide vaccines for the development of effective solutions to the SARS-CoV-2 coronavirus pandemic[EB/OL]. (2020-03-19)[2021-07-24]. https://finance.yahoo.com/news/generex-biotechnology-provides-guidance-safety 130010679. html.
[26] Min C. Clover biopharmaceuticals announces positive phase 1 data for its adjuvanted S-trimer COVID-19 vaccine candidates[EB/OL]. (2020-12-04)[2021-07-24]. http://www.cloverbiopharma.com.
[27] Wu S, Zhong G, Zhang J, et al.A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge[J]. Nat Commun,2020,11(1):4081-4087.
[28] Knoll MD, Wonodi C.Oxford-AstraZeneca COVID-19 vaccine efficacy[J]. Lancet,2021,397(10269):72-74.
[29] Balakrishnan VS.The arrival of Sputnik V[J]. Lancet Infect Dis,2020,10(20):1128-1128.
[30] ZEE5 News. COVID-19 vaccine latest ppdate: EpiVacCorona has no negative effect on health of embryo, says Russian watchdog[EB/OL]. (2020-12-30)[2021-07-24]. https://in.news.yahoo.com/covid-19-vaccine-latest-epivaccorona-155025252.html.
[31] Corbett KS, Flynn B, Foulds KE, et al.Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates[J]. N Engl J Med,2020,383(16):1544-1555.
[32] Anderson EJ, Rouphael NG, Widge AT, et al.Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults[J]. N Engl J Med,2020,383(25):2427-2438.
[33] Reuters. Turkey says China’s Sinovac COVID vaccine 91.25% effective in late trials[EB/OL]. (2020-12-24)[2021-07-24]. http://www.asahi.com/sp/ajw/articles/14059486.
[34] Zhu FC, Li YH, Guan XH, et al.Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial[J]. Lancet,2020,395(10240):1845-1854.
[35] Yang SL, Li Y, Dai LP, et al.Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials[J]. Lancet Infect Dis,2021, 21(8):1107-1119.
[36] Kaabi NA, Zhang YT, Xia SL, et al.Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults[J]. JAMA, 2021,326(1):35-45.
[37] Lazarus JV, Ratzan SC, Palayew A, et al.A global survey of potential acceptance of a COVID-19 vaccine[J]. Nat Med,2020,1(26):1-4.
[38] Wang J, Jing R, Lai X, et al.Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China[J]. Vaccines (Basel),2020,8(3):482-496.
[39] Harapan H, Wagner AL, Yufika A, et al.Acceptance of a COVID-19 vaccine in Southeast Asia: A cross-sectional study in Indonesia[J]. Front Public Health,2020,8:381-388.
[40] Mohaithef M, Padhi BK.Determinants of COVID-19 vaccine acceptance in Saudi Arabia: A web-based national survey[J]. J Multidiscip Health,2020,13:1657-1663.
[41] Garcia LY, Cerda AA.Contingent assessment of the COVID-19 vaccine[J]. Vaccine,2020,38(34):5424-5429.
[42] Reiter PL, Pennell ML, Katz ML.Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated?[J].Vaccine,2020,38(42):6500-6507.
[43] Malik AA, McFadden SM, Elharake J, et al. Determinants of COVID-19 vaccine acceptance in the US[J]. E Clinical Medicine,2020,26:100495-100503.
[44] Sarasty O, Carpio CE, Hudson D, et al.The demand for a COVID-19 vaccine in Ecuador[J]. Vaccine,2020,38(51):8090-8098.
[45] Salali GD, Uysal MS.COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey[J]. Psychol Med,2020,50(1):1-3. |
